stockportfolio.pro
Tectonic Therapeutic, Inc. (TECX)
Healthcare · Biotechnology · NasdaqGM
Tectonic Therapeutic, Inc. revenue & earnings — last 9 fiscal years
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — | — | — |
| Net income | $-18.65M | $-46.36M | $-72.97M | $-119.71M | $-119.13M | $-32.18M | $-42.82M | $-57.98M | $-74.15M |
| Net margin | — | — | — | — | — | — | — | — | — |
Source: Tectonic Therapeutic, Inc. SEC filings (10-K).
Explore 9 years of Tectonic Therapeutic, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track TECX in your portfolio →
Tectonic Therapeutic, Inc. financial history by metric
About Tectonic Therapeutic, Inc.
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.
Tectonic Therapeutic, Inc. — frequently asked questions
What is Tectonic Therapeutic, Inc.'s revenue?
Tectonic Therapeutic, Inc. (TECX) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Tectonic Therapeutic, Inc. profitable?
No — TECX reported a net loss of $-74.15M in fiscal 2025.
What is TECX's P/E ratio?
Tectonic Therapeutic, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Tectonic Therapeutic, Inc. have?
As of fiscal year 2025, TECX carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Tectonic Therapeutic, Inc.'s market cap?
Tectonic Therapeutic, Inc. (TECX) has a market capitalization of about $555.32M, based on the latest data in our nightly-refreshed cache.
When does Tectonic Therapeutic, Inc.'s fiscal year end?
TECX's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Tectonic Therapeutic, Inc.'s official SEC filings (10-K and 10-Q), covering 9 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.